ArticleInfectious diseases (London, England)2016
Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.
Article in Infectious diseases (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- The interplay between host immunity andmBio · 2025Review
- Bacterial Organelles in Iron Physiology.Molecular microbiology · 2024Review
- Review
- Systemic neutrophil degranulation and emergency granulopoiesis in patients with Clostridioides difficile infection.Anaerobe · 2024Article
- The Strain and the Clinical Outcome ofOpen forum infectious diseases · 2024Article
- Article
- ZupT Facilitates Clostridioides difficile Resistance to Host-Mediated Nutritional Immunity.mSphere · 2020Article
- Treatment of Severe and Fulminnant Clostridioides difficile Infection.Current treatment options in gastroenterology · 2019Review
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment ofFrontiers in microbiology · 2018Review
- Article
- Current knowledge on the laboratory diagnosis ofWorld journal of gastroenterology · 2017Review
- Infection: Modulation of Clostridium difficile infection by dietary zinc.Nature reviews. Gastroenterology & hepatology · 2016Article
- Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection.Nature medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundClostridium difficile infection (CDI) causes a mild to moderate colitis in most patients, but some, especially older adults, develop severe, adverse outcomes. Biomarkers predicting outcomes are needed to optimize treatments. This study tested whether fecal calprotectin associated with a composite primary outcome of complicated CDI (intensive care unit admission, colectomy, or death due to CDI within 30 days of diagnosis) and/or 8-week recurrence.
methodsStool was collected in Cary-Blair media at the time of diagnosis from inpatients of age >60 years that tested positive for C. difficile (enzyme immunoassay [EIA] for toxin A/B or polymerase chain reaction for the tcdB gene). Fecal calprotectin was measured and normalized to solid stool weight. Analysis was performed using logistic regression. Variables were selected for the final model using likelihood ratio tests.
resultsFifty patients were included with a mean age 72.8 (± 7.5), and 13 (26%) developed the primary outcome. Clinical variables such as age, gender, and comorbid disease did not associate with complicated CDI/recurrence, nor did traditional biomarkers such as serum albumin or white blood cell count. A high normalized fecal calprotectin (>2000 μg/g) associated with the primary outcome in the final model after adjustment for gender and detectable fecal toxin(s) by EIA (OR 24.9, 95% CI 2.4-257.9, p = 0.007) with a specificity of 91.9%.
conclusionThis study provides evidence that fecal calprotectin level associates with complications from CDI in older adults. Further studies are required to validate these findings in larger cohorts and incorporate them into clinical prediction algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.